News & Updates

Mitapivat, a first-in-class, oral, allosteric activator of pyruvate kinase (PK), breaks new ground in the global phase III ENERGIZE study, the first trial to demonstrate the potential of an oral treatment for both alpha- and beta-non-transfusion-dependent thalassemia (NTDT).

Patients undergoing a shorter-than-recommended fasting period prior to coronary angiography have significantly higher satisfaction scores, according to a study. This finding highlights the feasibility of revised fasting protocols.

Gratitude is associated with increased longevity among older females, a population-based study has shown. 

According to local data presented at AIM 2024, approximately two-thirds of middle-aged and older residents in Hong Kong have systolic blood pressure (SBP) >120 mm Hg. A high prevalence of cerebral small vessel disease (SVD) is also found in this population.

Treatment with the oral selective cardiac myosin inhibitor aficamten produced improvements in peak oxygen uptake in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), as shown in the phase III SEQUOIA-HCM trial.